Portal de investigación
Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- González García A
- Fabregate M
- Manzano L
- Guillén Del Castillo A
- Rubio Rivas M
- Argibay A
- Marín Ballvé A
- Rodríguez Pintó I
- Pla Salas X
- Marí-Alfonso B
- Callejas Moraga E
- Colunga Argüelles D
- Sáez Comet L
- González-Echávarri C
- Ortego-Centeno N
- Vargas Hitos JA
- Trapiella Martínez L
- Herranz Marín MT
- Chamorro AJ
- Perales Fraile I
- Madroñero Vuelta AB
- Sánchez Trigo S
- Tolosa Vilella C
- Fonollosa Pla V
- Simeón Aznar CP
- RESCLE Investigators, Systemic Autoimmune Diseases Study Group (GEAS)
Grupos
Abstract
OBJECTIVES: Left ventricular diastolic dysfunction (LVDD) remains poorly studied in Systemic Sclerosis (SSc). To determine the prevalence and to define factors associated with LVDD and survival in a large cohort of patients with SSc. METHODS: An observational study was conducted with data from the multicentre Spanish Scleroderma Registry (RESCLE) to identify factors associated with LVDD and estimate survival. RESULTS: Out of 1517 patients, 319 (21.0%) had LVDD. The subset of sine scleroderma SSc was associated to LVDD (14.7% vs. 10.6%, p =0.048), whilst diffuse cutaneous SSc was more prevalent in non-LVDD (16.0 % vs. 21.2%, p =0.041). Multivariable analysis identified that LVDD was associated with older age at diagnosis of SSc (OR 1.05; 95% CI 1.04 to 1.06), longer time from diagnosis (OR 1.04; 95% CI 1.03 to 1.06), presence of telangiectasia (OR 1.42; 95% CI 1.08 to 1.88), treatment with calcium channel blockers (CCB) (OR 1.51; 95% CI 1.16 to 1.96), and inversely related to angiotensin-converting-enzyme inhibitors (ACEi) use (OR 0.59; 95% CI 0.44 to 0.80). SSc patients with LVDD had increased mortality (23.8 vs. 17.4%, p =0.010) and shortened survival from the first SSc symptom (p =0.040), even though it was not found to be an independent risk factor for death. CONCLUSIONS: LVDD is relatively common in SSc patients, and it is associated with worst prognosis, older age, longer time from diagnosis of SSc, presence of telangiectasia and vasodilator treatment.
Copyright © 2022. Published by Elsevier Inc.
Datos de la publicación
- ISSN/ISSNe:
- 0049-0172, 1532-866X
- Tipo:
- Article
- Páginas:
- 152033-152033
- PubMed:
- 35691226
- Factor de Impacto:
- 1,471 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
SEMINARS IN ARTHRITIS AND RHEUMATISM W B SAUNDERS CO-ELSEVIER INC
Citas Recibidas en Web of Science: 15
Documentos
- No hay documentos
Filiaciones
Keywords
- Anticentromere; Antinuclear antibodies, Diffuse scleroderma, Limited scleroderma; Interstitial pneumonia; Pulmonary hypertension; Systemic sclerosis
Campos de Estudio
Cita
González A,Fabregate M,Manzano L,Guillén Del Castillo A,Rubio M,Argibay A,Marín A,Rodríguez I,Pla X,Marí B,Callejas E,Colunga D,Sáez L,González C,Ortego N,Vargas JA,TODOLÍ JA,Trapiella L,Herranz MT,FREIRE M,Chamorro AJ,Perales I,Madroñero AB,Sánchez S,Tolosa C,Fonollosa V,Simeón CP,RESCLE SADSG(. Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry. Semin Arthritis Rheum. 2022. 55. p. 152033-152033. IF:5,000. (2).